ArticleBMJ (Clinical research ed.)2020
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
Article in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 97 citations in OpenAlex.
- A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.Clinical and translational science · 2023Trial
- Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis.Clinical pharmacology and therapeutics · 2026Article
- Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries.JAMA health forum · 2026Article
- Discordance in orphan drug approvals between the U.S. Food and Drug Administration and the European Medicines Agency: A retrospective observational analysis.PLoS medicine · 2026Observational
- The launch and diffusion of new patented medicines by therapeutic value.Health affairs scholar · 2026Article
- Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003-2024).Clinical drug investigation · 2026Article
- Modern Clinical Trials: Seamless Designs and Master Protocols.Cancer medicine · 2026Review
- Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development Strategies.Journal of market access & health policy · 2026Article
- Accelerating cancer therapy review: a cross-sectional analysis of expedited approval in China, 2005-2021.BMC cancer · 2026Article
- FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA.Frontiers in pharmacology · 2026Article
- Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes.Cancer management and research · 2026Review
- Targeting Undruggable Proteins: The siRNA Revolution Beyond Small Molecules - Advances, Challenges, and Future Prospects in Therapeutic Innovation.Current gene therapy · 2026Review
- Comparison of drug approvals of the FDA and EMA between 2013 and 2023.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions.Health economics review · 2025Article
- Research and development investments for biologics independently developed by US biotechnology startups, 2017-2023.Health affairs scholar · 2025Article
- An overview of randomized phase III clinical trials of cancer nanomedicines.Cancer pathogenesis and therapy · 2025Review
- Added Therapeutic Benefits of Top-Selling Drugs in Japan: A Cross-Sectional Study Using Health Technology Assessment.Clinical and translational science · 2025Article
- Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry.Pharmaceutics · 2025Review
- Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study.JRSM open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo characterize the therapeutic value of new drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the association between these ratings and regulatory approval through expedited programs.
designRetrospective cohort study.
settingNew drugs approved by the FDA and EMA between 2007 and 2017, with follow-up through 1 April 2020. DATA SOURCES: Therapeutic value was measured using ratings of new drugs by five independent organizations (Prescrire and health authorities of Canada, France, Germany, and Italy).
main outcome measuresProportion of new drugs rated as having high therapeutic value; association between high therapeutic value rating and expedited status.
resultsFrom 2007 through 2017, the FDA and EMA approved 320 and 268 new drugs, respectively, of which 181 (57%) and 39 (15%) qualified for least one expedited program. Among 267 new drugs with a therapeutic value rating, 84 (31%) were rated as having high therapeutic value by at least one organization. Compared with non-expedited drugs, a greater proportion of expedited drugs were rated as having high therapeutic value among both FDA approvals (45% (69/153)
conclusionsLess than a third of new drugs approved by the FDA and EMA over the past decade were rated as having high therapeutic value by at least one of five independent organizations. Although expedited drugs were more likely than non-expedited drugs to be highly rated, most expedited drugs approved by the FDA but not the EMA were rated as having low therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.